Fluvastatin
Top View
- STATIN-FIBRATE REPORT: Focus on Safety VHA Pharmacy Benefits Management-Strategic Healthcare Group and the Medical Advisory Panel
- Therapeutic Class Overview Statins (HMG-Coa Reductase Inhibitors)
- Australian Public Assessment Report for Pitavastatin
- 1. NAME of the MEDICINAL PRODUCT Fluvastatin 20 Mg / 40
- For Review at September 24, 2020, Meeting: Antihyperlipidemics
- Simultaneous Spectrophotometric Estimation of Fluvastatin And
- Fenofibrate and Derivatives
- Nilemdo, INN-Bempedoic Acid
- Fluvastatin Mitigates SARS-Cov-2 Infection in Human Lung Cells
- TRICOR® 48 Mg and 145 Mg (Fenofibrate Tablets)
- Baseline Low-Density Lipoprotein Cholesterol Predicts the Benefit Of
- Fluvastatin Inhibits HMG-Coa Reductase and Prevents Non
- Therapeutic Class Overview Bile Acid Sequestrants
- Nexlizet (Bempedoic Acid/Ezetimibe) P&T Approval Date 8/2020 Effective Date 11/1/2020; Oxford Only: N/A
- Study Protocol 1002-048 Amendment 2, 10 February 2017
- Pharmacologic Therapies
- Lescol Lescol XL
- Fluvastatin XL Cuts LDL Level with Less Myalgia